Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetylsalicylic Acid and L-arginine to Prevent Preeclampsia
NCT02838030Phase 2Suspended
- Sponsor
- Universidad de Guadalajara
- Start
- Jul 2018
- Primary completion
- Jul 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in preeclampsia comparing acetylsalicylic acid and L-arginine with acetylsalicylic acid and placebo (2 arms). Primary endpoints: Incidence of preeclampsia at 37 weeks and Severity of preeclampsia at 37 weeks. Started Jul 2018; status: suspended.
02
Drugs
arginine
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT02838030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02838030.